Drug intelligence / Profile preview

BCC0100281

Development stage: Unknown
Lead developer: University of Nebraska Medical Center

Overview

BCC0100281: sourced facts only. name: "The screening compound BCC0100281 (1), was previously identified as an inhibitor of 17β-HSD10." [PMID:39618963]; target: "The screening compound BCC0100281 (1), was previously identified as an inhibitor of 17β-HSD10." [PMID:39618963]; developer: "Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center Omaha Nebraska 68198 USA [email protected]." [PMID:39618963]

Targets

ABAD (17-beta-hydroxysteroid dehydrogenase type 10)

Beyond the preview

Go deeper on BCC0100281.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCC0100281.